Wednesday, November 21st, 2018

Dorothy Nadolny Cardio-Metabolic Disease Research Hub hosts School II of TREATMENT

The epidemic of fatty liver diseases: risk factors, treatment and extrahepatic consequences

Tayarut hall, Hadassah Medical Center, Ein Kerem

08:40 Gathering and breakfast

09:00-09:30 Ilan Matok (HUJI, Israel)
Statistic analyses of large data

09:30—09:40 Rifaat Safadi (Hadassah, Israel): Greetings and overview of the fatty liver epidemics.

Liver signaling in the transition from NAFLD to NASH

Chair: Rifaat Safadi

9:40-10:20 Raul Mendez (IRB, Spain)
Translational regulation of the adaptive liver stress response

10:20-10:45 Angela Valverde (CSIC-UAM, Spain)
Novel players in the progression and treatment of non-alcoholic liver disease associated to obesity

10:45-11:10 Oren Tirosh (HUJI, Israel)
Lipotoxicity and hypoxic signaling in NAFLD progression

11:10-11:30 Coffee break
Modulation of liver metabolism by drugs and other interventions

Chair: Isabel Fabregat

11:30-11:55  Yaacov Bar Tana (HUJI, Israel)
Fatty liver – More than liver pathology

11:55-12:20  Yossi Tam (HUJI, Israel)
Reversal of fatty liver by peripheral CB1 receptor blockade is
Sirt1/PPARα dependent

12:20-12:45  Sigal Fishman (TLVMC, Israel)
Glucose dependent insulinotrophic polypeptide (GIP), a new
player in the combat against obesity and NAFLD

12:45-13:10  Shira Zelber Sagi (Haifa U & TLVMC, Israel)
NAFLD as a lifestyle oriented and treated disease

13:10-14:00 Lunch break

14:00-14:45  Shai Melcer (CEO of BioHouse, Israel)
From bench to business- visit to the Biohouse

Subversion of fatty liver by nutrition and beyond

Chair: Oren Shibolet (TLVMC, Israel)

14:45-15:25  Elisabetta Bugianesi (UDT, Italy)
The clinical spectrum of NAFLD

15:25-15:50  Yftach Gepner (TAU, Israel)
Diet-induced hepatic fat content loss; benefits beyond
concurrent decreases in visceral adiposity

15:50-16:15  Eyal Shteyer (SZMC, Israel)
Fatty liver in children- is it different than in adults?

16:15-16:40  Oren Shibolet (TLVMC, Israel)
Drug induced lipotoxicity

16:40-17:05  Isabel Fabregat (BU, Spain)
TGF-beta: a targetable pathway in liver diseases?

17:05-17:30  Jan Eriksson (UU, Sweden) Clinical trials in NAFLD and the
implications for patients receiving antipsychotic drug

17:30-17:40  Boaz Tirosh (HUJI, Israel)
Concluding remarks

Organized by: Boaz Tirosh (HUJI), Shira Zelber Sagi (Haifa U & TLVMC)
The seminar is university course no.64818 and equals 0.5 credits